The 7 analysts offering 12-month price forecasts for Dicerna Pharmaceuticals Inc have a median target of 38.00, with a high estimate of 38.25 and a low estimate of 26.00. The median estimate represents a -0.21% decrease from the last price of 38.08.
The current consensus among 8 polled investment analysts is to Hold stock in Dicerna Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.54
Reporting Date Mar 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.